Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine for OCD and GAD
NCT00674219Phase 3Completed
- Sponsor
- University of California, Los Angeles
- Start
- May 2005
- Primary completion
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of memantine in obsessive compulsive disorder (OCD) and generalized anxiety disorder (GAD), sponsored by University of California, Los Angeles. Primary endpoint: Psychometric Scores (Yale-Brown Obsessive Compulsive Scale / Hamilton Anxiety Rating Scale) at 12 weeks. Started May 2005; status: completed.
02
Drugs
memantine
03
Conditions
obsessive compulsive disorder (OCD)generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00674219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00674219.